StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Tuesday. The brokerage issued a sell rating on the stock.

Oragenics Trading Up 6.5 %

Shares of NYSE OGEN opened at $1.15 on Tuesday. The company has a market cap of $5.15 million, a PE ratio of -0.12 and a beta of 0.31. The firm has a 50 day moving average price of $1.98. Oragenics has a 52 week low of $1.02 and a 52 week high of $7.74.

Oragenics (NYSE:OGEN) last announced its earnings results on Friday, March 29th. The company reported ($5.48) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oragenics

A number of large investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its position in Oragenics by 8.1% during the first quarter. State Street Corp now owns 495,563 shares of the company’s stock worth $171,000 after purchasing an additional 37,338 shares during the period. Renaissance Technologies LLC boosted its position in Oragenics by 24.4% during the fourth quarter. Renaissance Technologies LLC now owns 288,398 shares of the company’s stock worth $30,000 after purchasing an additional 56,498 shares during the period. Finally, Millennium Management LLC boosted its position in Oragenics by 591.6% during the second quarter. Millennium Management LLC now owns 128,733 shares of the company’s stock worth $45,000 after purchasing an additional 110,119 shares during the period. Institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.